Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Qutenza versus low-dose capsaicin for post-surgical neuropathic pain
NL-OMON55934Phase 3Recruiting
- Sponsor
- Averitas Pharma, Inc.
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of capsaicin in Neuralgia (2 arms), sponsored by Averitas Pharma, Inc. Primary endpoints: Change from baseline to Week 12 in 24-hour average pain intensity and Change from baseline to average pain intensity over Weeks 2 to 12. Started Sep 2022; status: recruiting.
02
Drugs
capsaicin
03
Conditions
Neuralgia
Beyond the preview
Go deeper on NL-OMON55934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55934.